The emerging therapy of the medication represents a exciting development in the care of type 2 diabetes. Distinct from existing drugs, tirzepatide impacts two pathways – GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) – leading to greater glucose regulation and possible weight reduct